期刊
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
卷 35, 期 -, 页码 2-13出版社
ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.semcdb.2014.08.010
关键词
Experimental disease models; Necroptosis; RIPK1/3; MLKL; Methods
资金
- FP6 ApopTrain [MRTNCT-035624]
- FP7 EC RID Integrated Project, Apo-Sys [FP7-200767]
- Euregional PACT II
- Inter-university Attraction Poles [IAP 6/18, IAP 7/32]
- Research Foundation Flanders [FWO G.0875.11, FWO G.0973.11N, FWO G.0A45.12N]
- Ghent University (MRP, GROUP-ID consortium)
- Flanders Institute for Biotechnology (VIB)
- Flemish Government [BOF09/01M00709]
- FWO
- Marie Curie COFUND initiative
Over the last decade, our picture of cell death signals involved in experimental disease models totally shifted. Indeed, in addition to apoptosis, multiple forms of regulated necrosis have been associated with an increasing number of pathologies such as ischemia-reperfusion injury in brain, heart and kidney, inflammatory diseases, sepsis, retinal disorders, neurodegenerative diseases and infectious disorders. Especially necroptosis is currently attracting the attention of the scientific community. However, the in vivo identification of ongoing necroptosis in experimental disease conditions remains troublesome, mainly due to the lack of specific biomarkers. Initially, Receptor-Interacting Protein Kinase 1 (RIPK1) and RIPK3 kinase activity were uniquely associated with induction of necroptosis, however recent evidence suggests pleiotropic functions in cell death, inflammation and survival, obscuring a clear picture. In this review, we will present the last methodological advances for in vivo necroptosis identification and discuss past and recent data to provide an update of the so-called necroptosis-associated pathologies. (C) 2014 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据